Vimarsana
Biggest News Aggregation in the World

Page 3 - Allogeneic News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Allogeneic. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Allogeneic Today - Breaking & Trending Today

Vycellix, Inc.: Vycellix Presents Proof-of-Concept Data for VY-UC Allogeneic Cell Therapy Platform at the International Society for Cell & Gene Therapy (ISCT) Annual Meeting, Paris - Vimarsana News

Vycellix, Inc.: Vycellix Presents Proof-of-Concept Data for VY-UC Allogeneic Cell Therapy Platform at the International Society for Cell & Gene Therapy (ISCT) Annual Meeting, Paris

Single-Step CD45-Engager Strategy Generates Immune-Privileged Cells with Abrogation of Host Cellular Immune Responses Being Developed to Eliminate the Need for Complex, Expensive Gene-Editing Approaches

Cellectis Showcased Preclinical Data at an Oral Presentation and Two Poster Presentations at the 29th International Society for Cell & Gene Therapy (ISCT 2023) Annual Event - Vimarsana News

Cellectis Showcased Preclinical Data at an Oral Presentation and Two Poster Presentations at the 29th International Society for Cell & Gene Therapy (ISCT 2023) Annual Event

Preclinical data on UCART20x22, Cellectis’ first allogeneic dual CAR T-cell product candidate to treat B-NHL, presented at an oral session Encouraging data presented on gene editing process... | June 5, 2023

Allogene Therapeutics Presents Updated ALLO-501/501A Phase 1 Data in Large B Cell Lymphoma at the American Society of Clinical Oncology (ASCO) Annual Meeting - Vimarsana News

Allogene Therapeutics Presents Updated ALLO-501/501A Phase 1 Data in Large B Cell Lymphoma at the American Society of Clinical Oncology (ASCO) Annual Meeting

Long Term Follow Up Data from Phase 1 ALPHA/ALPHA2 Trials Demonstrate Potential of Allogeneic CD19 CAR T to Generate Durable Complete Responses Similar to Approved Autologous Therapies Presentation... | June 3, 2023

Celularity Tissue Factor Gene Knockout of Allogeneic Stromal Cells Significantly Lowers Thrombotic Effects; Study Highlights Critical Importance of Gene Editing Capability - Vimarsana News

Celularity Tissue Factor Gene Knockout of Allogeneic Stromal Cells Significantly Lowers Thrombotic Effects; Study Highlights Critical Importance of Gene Editing Capability

Data published online in the journal Cytotherapy demonstrate that CRISPR-mediated tissue factor gene knockout in allogeneic stromal cells leads to significantly lower tissue factor expression,... | June 1, 2023

Precision BioSciences Provides Update on Allogeneic CAR T Programs and Regulatory Path Forward - Vimarsana News

Precision BioSciences Provides Update on Allogeneic CAR T Programs and Regulatory Path Forward

Azer-Cel Safety Profile was Significantly Improved Compared to Prior Cohorts in Patients Dosed Using Optimized Product at Lower Intensity Lymphodepletion; No Grade 3 or Greater Allogeneic CAR T... | May 31, 2023